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a  b  s  t  r  a  c  t
In  the  present  work,  the  antiviral  activity  of brequinar  (BQR)  against  the  replication  of  Cantagalo  virus
was  evaluated.  BQR  is  a  potent  inhibitor  of  cellular  dihydroorotate  dehydrogenase,  an  enzyme  of the  de
novo  pyrimidine  biosynthetic  pathway.  Infection  in the  presence  of  0.5 M BQR  reduced  virus  progeny
production  by  >90%,  revealing  an  EC50 (drug  concentration  required  to inhibit  50%  of virus  replication)
of  0.017  M. Replication  of  other  orthopoxviruses  was  also  inhibited  by BQR  at  similar  levels. In the
presence  of  the  drug,  virus  early  proteins  accumulated  to control  levels,  whereas  late  gene  expression
was  severely  impaired.  This  result  was  conﬁrmed  by indirect  immunoﬂuorescence  assays  and  analysis  of
time-regulated  expression  of  a  reporter  gene  under  the control  of  a virus  promoter.  Both  assays  revealedaccinia virus
oxvirus
nearly  90%  inhibition  of late  gene  expression.  BQR  also  blocked  virus  DNA  replication,  which  accounted
for  the  subsequent  inhibition  of  virus  late  gene  expression.  The  ablation  of  virus  DNA  replication,  late
gene  expression  and  infectious  progeny  production  was  restored  to  control  levels  when  infected  cells
were  co-treated  with  uridine  (URD)  and  BQR.  These  data  demonstrated  that  BQR  targeted  virus  DNA
synthesis  by  depleting  the  cellular  pyrimidine  pool,  which  was  bypassed  by  the  salvage  pathway  when
ll  cult
nd thURD  was added  to  the  ce
© 2011 Elsevier B.V. a
. Introduction
Cantagalo virus (CTGV) is a strain of vaccinia virus (VACV) that
as originally isolated in 1999 from lesions on cows and dairy
orkers during an outbreak of a pustular skin disorder in dairy
arms in Rio de Janeiro State, Brazil [1]. This zoonosis was  initially
etected in southeastern states of the country, but its spread to and
stablishment in different regions, including the Brazilian Amazon,
ave been reported over the last decade [2–4]. The uncontrolled
issemination of CTGV infection in Brazil is worrisome because
mportant economic issues may  arise in affected farms, which have
heir income based mostly on dairy activities [4]. In addition, no
ntiviral therapy is currently available for CTGV or other poxvirus-
elated infections.
Poxviruses are large, double-stranded DNA-containing viruses
hat replicate exclusively in the cell cytoplasm. The replicative cycle
s complex and involves a tight control of virus gene expression
n a cascade fashion. Therefore, virus DNA replication occurs after
he early stage of gene expression has succeeded and, on the other
and, the production of new genome molecules is an essential pre-
equisite for completion of the pos-replicative phases of the virus
ycle [5].
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Over the last two  decades there have been numerous studies
focusing on the identiﬁcation of anti-poxvirus agents. The rele-
vance of these efforts is based on the concern of a possible use
of variola virus as a bioweapon, the elevated number of cowpox
virus infections in pet and zoo animals in Europe, the outbreaks of
monkeypox virus in Africa, the occurrence of severe adverse effects
following smallpox vaccination [6], and the widespread dissemina-
tion of CTGV zoonosis in Brazil [2].
Our group has reported the antiviral activity of several
immunosuppressants, such as cyclosporine A (CsA), FK-506 and
azathioprine, as well as non-immunosuppressive drugs against the
replication of distinct VACV strains, including CTGV [7–12]. Bre-
quinar (BQR) is an immunosuppressive and antiproliferative drug
effective against allograft and xenograft rejection following trans-
plantation [13,14]. It inhibits the proliferation of T-cells, production
of antibodies and tumour growth [15]. The mechanism of action of
BQR probably relies on inhibition of dihydroorotate dehydrogenase
(DHODH) activity, the fourth enzyme and a rate-limiting step in the
de novo biosynthesis of pyrimidines [16]. Therefore, BQR probably
exerts its effect by depleting the cellular pyrimidine pool, which
is needed for RNA and DNA synthesis. Nevertheless, inhibition of
tyrosine phosphorylation has been reported as another activity of
Open access under the Elsevier OA license.BQR [17]. Here we have investigated the antiviral efﬁcacy of BQR on
the replication of CTGV. We  show that BQR severely inhibited the
production of infectious virus and the late stages of gene expres-
sion. The drug speciﬁcally targeted virus DNA synthesis since the
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ffect was reversed by the addition of uridine (URD), which leads
o the bypass of the de novo synthesis of pyrimidines.
. Materials and methods
.1.  Brequinar
BQR was provided by DuPont Merck Pharmaceutical Com-
any (Wilmington, DE). The drug was dissolved in 100% dimethyl
ulphoxide (DMSO) and was stored at −20 ◦C.
.2. Cells and viruses
Monolayer  cultures of BSC-40 (African green monkey kidney)
ells were propagated in Dulbecco’s Modiﬁed Eagle Medium (Invit-
ogen, Carlsbad, CA) supplemented with 5% heat-inactivated foetal
ovine serum, 100 g/mL streptomycin and 500 U/mL penicillin at
7 ◦C [12]. In this study, the following viruses were used: CTGV iso-
ate CM-01 [1]; VACV strains IOC clone A1-1-1 [1], WR and Wyeth;
owpox virus (CPXV) strain Brighton-Red (originally obtained from
ichard Moyer, University of Florida, FL); and recombinant CTGV
xpressing the -galactosidase gene of Escherichia coli (CTGV-Gal)
nder the control of an early/late VACV promoter (Reis and Damaso,
npublished data). All viruses were available in the laboratory’s col-
ection and were routinely propagated and titered by plaque assay
n BSC-40 cells [12].
.3.  Virus infection and yield analysis
For analysis of intracellular virus yield, cells were infected with
000 plaque-forming units (PFU) of CTGV (1 × 106 cells per plate)
or 2 h (adsorption period). The inocula were removed and the cells
ere treated with either 0.1% DMSO (control) or BQR concentra-
ions ranging from 0.005 M to 10 M.  After 24 h, the monolayers
ere harvested and were processed for virus titration by plaque
ssay [12]. In experiments where a multiplicity of infection (MOI)
f 1 PFU/cell was used, the adsorption period was 30 min. In assays
o determine the effect of BQR on the replication of VACV-IOC,
ACV-WR, VACV-Wyeth and CPXV, the infected cells were treated
ith 0.1% DMSO or 5 M BQR for 24 h. For one-step growth assays,
0 M BQR was used and CTGV-infected cells were harvested at 3,
, 8, 16, 18, 20 and 24 h. In some assays, URD was added at 50, 100
r 300 M.  The procedures for obtaining cell lysates and determin-
ng virus titres were carried out essentially as described above. To
valuate the virucidal effect of BQR, puriﬁed CTGV (4 × 106 PFU/mL)
1] was incubated with BQR at 0.1, 1 and 5 M or with 0.1% DMSO
control) for 1 h at room temperature with occasional shaking, fol-
owed by titration as described above. All measurements of virus
roduction are expressed as the average of at least two  experiments
erformed in duplicate.
.4.  Toxicity assays
The  neutral-red uptake assay was used to evaluate cell via-
ility essentially as described [7]. BSC-40 cells were seeded in
6-well plates in the presence of concentrations of BQR ranging
rom 0.01 M to 75 M for 24 h. Control cells were incubated with
.1% DMSO. Neutral red was methanol/acetic acid-extracted from
ells and was quantitated at an absorbance of 490 nm (A490) [7]. All
easurements expressed the average of four independent assays.
.5. Western blot assayBSC-40  cells were infected with CTGV at a MOI  of 1 and were
reated with either 0.1% DMSO (control) or 30 M BQR. In some
ssays, URD was added at 100 M or 300 M.  At different times postl of Antimicrobial Agents 38 (2011) 435– 441
infection,  cells were harvested in sodium dodecyl sulphate (SDS)-
containing sample buffer and were subjected to electrophoresis
in 11.5% SDS polyacrylamide gel electrophoresis (PAGE) [7,12].
Proteins were transferred to nitrocellulose membranes and West-
ern blot analysis was carried out essentially as described [7,10].
Blots were probed with rabbit anti-VACV structural proteins [10],
mouse anti--tubulin (Sigma-Aldrich, St Louis, MO)  or rabbit anti-
F11 antibody [10]. The bound antibodies were detected using
anti-rabbit or anti-mouse antibody conjugated to horseradish per-
oxidase IgG (Santa Cruz Biotechnology, Santa Cruz, CA), followed by
incubation with Super Signal West Pico (Thermo Scientiﬁc, Rock-
ford, IL).
2.6.  Measurement of ˇ-galactosidase activity
BSC-40 cells were infected with CTGV-Gal at a MOI  of 1 and
were treated with 0.1% DMSO, 30 M BQR or 40 g/mL cytosine
arabinoside (Ara-C). At 6 h and 24 h post infection, cells were har-
vested in Milli-Q water and were processed for determination
of -galactosidase activity essentially as described [12]. For each
duplicate sample, 250 g/mL of the substrate O-nitrophenyl--d-
galactopyranoside (Sigma-Aldrich) was added and reactions were
stopped with 230 M Na2CO3 when a light yellow colour was
developed. Absorbance was measured at A420. All measurements
expressed the average of two  independent assays performed in
eight replicates.
2.7.  Indirect immunoﬂuorescence assays
BSC-40 cells were grown on 13-mm round glass coverslips
in 24-well plates and were infected with CTGV at a MOI  of 1.
After 20 h in the presence of 30 M BQR or 0.1% DMSO (control),
the monolayers were ﬁxed in 4% paraformaldehyde/phosphate-
buffered  saline (PBS) and were permeabilised using 0.5% Triton
X-100 for 5 min  as described [18]. The coverslips were then incu-
bated with 50 mM NH4Cl for 30 min, followed by 1% bovine serum
albumin/PBS for 1 h. Cells were stained with rabbit anti-VACV struc-
tural proteins and mouse anti-D8 (kindly provided by Geoffrey
Smith, Imperial College, London, UK) for 1 h, followed by species-
speciﬁc ﬂuorescent secondary antibodies (rabbit anti-IgG Alexa488
and mouse anti-IgG Alexa555; Invitrogen). DNA was  stained with
1 g/mL 4′-6-diamidino-2-phenylindole (DAPI) for 5 min. Samples
were analysed with a Zeiss Axio Observer Z1 microscope (Carl Zeiss
Inc., Thornwood, NY) using Axiovision software. For quantitation of
infected cells, 1095 control cells and 1065 BQR-treated cells were
counted in three independent assays.
2.8. Analysis of DNA replication by slot-blot assay
Cells were infected with CTGV at a MOI  of 1, incubated or
not with 30 M BQR, and harvested at different times post infec-
tion. In some assays, URD was  added at 100 M or 300 M.  Cell
extracts were prepared in 10× saline–sodium citrate (SSC) buffer,
1 M NH4Ac as described [12], and samples were applied to nylon
membranes in triplicate, under vacuum, using a Minifold® II Slot-
Blot apparatus. DNA was denatured in situ. Blots were hybridised to
the HindIII D fragment of the VACV genome after nick-translation
labelling with [-32P]dCTP (Perkin-Elmer Life Sciences, Waltham,
MA), followed by exposure to X-ray ﬁlms [10,12]. At least two
independent assays were performed and applied onto nylon mem-
branes in three replicates.
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Fig. 1. Antiviral effect and cytotoxicity of brequinar (BQR). (a) Dose-dependent inhi-
bition of virus progeny production. Cells were infected with 1000 plaque-forming
units  (PFU) of Cantagalo virus (CTGV) and were incubated with the indicated concen-
trations of BQR. Virus yield was determined at 24 h post infection. (b) The indicated
concentrations of BQR were added to BSC-40 monolayers for 24 h. Cell viability was
























Autoradiographs were scanned and densitometry analysis was
erformed using the program Scion Image (Beta release 4; Scion
orporation, Frederick, MD)  as described [10].
. Results
.1. Effect of brequinar on virus yield
As a ﬁrst approach to evaluate the antiviral potential of BQR,
roduction of infectious particles in infected cells treated with
ncreasing concentrations of the drug for 24 h was investigated. BQR
ed to severe inhibition of CTGV yield in a dose-dependent manner,
eaching nearly 98% at 0.5 M (Fig. 1a). Similar levels of inhibition
ere also observed when virus plaque formation was  evaluated
n the presence of BQR (data not shown). As shown in Fig. 1b, the
ntiviral activity was not due to cytotoxic effects of BQR since cell
iability remained nearly 80% at concentrations up to 75 M BQR
50% cytotoxic concentration (CC50) > 75 M].  Based on these data,
he EC50 was calculated to be 0.017 ± 0.05 M,  and the selective
ndex (CC50/EC50) was estimated to be >4410.
The effect of BQR on the replication of other orthopoxviruses
as also analysed. The MOI  was elevated to 1 and infected cells
ere incubated for 24 h with 5 M BQR. All VACV strains tested
s well as CPXV had the production of infectious particles severely
nhibited by BQR (Fig. 2a). A similar inhibitory effect was observed
t 1 M BQR (data not shown). Whether BQR could affect thel of Antimicrobial Agents 38 (2011) 435– 441 437
infectivity  of CTGV particles was  also tested. For that, puriﬁed CTGV
particles were incubated with different concentrations of BQR, fol-
lowed by titration in BSC-40 cells. As shown in Fig. 2b, BQR had no
effect on the infectivity of CTGV particles (virucidal effect).
3.2.  Effect of brequinar during one-step replication cycles
3.2.1.  Analysis of the production of infectious particles and
protein  accumulation
To  evaluate better the stages of the virus replicative cycle tar-
geted by BQR, the next set of assays was performed using a MOI
of 1 and 30 M BQR. Analysis of one-step growth curves demon-
strated that BQR completely abolished the formation of infectious
CTGV particles since the initial hours of infection under these condi-
tions. On the other hand, virus yields progressively increased after
8 h post infection in untreated cells (Fig. 3a). To map  the stage of
the virus cycle inhibited by BQR, accumulation of virus early and
late proteins was evaluated by Western blot. As a marker for the
early stage, F11 was detected, which is synthesised at the early
phase of the cycle but accumulates until the late stages [10]. Detec-
tion of CTGV structural proteins (anti-VACV), which are primarily
expressed at the late stages after 8 h post infection, was taken as a
marker of post-replicative gene expression. As observed in Fig. 3b,
BQR did not affect F11 accumulation in BQR-treated cells compared
with untreated cells. On the other hand, accumulation of CTGV
structural proteins was  completely abrogated during infection in
the presence of BQR (Fig. 3b). This result indicated that BQR did not
affect virus early gene expression, but had a severe effect on the
late stage of the virus cycle.
To  conﬁrm this result, the effect of BQR on the expression of
a reporter gene under the control of a VACV early/late promoter
was evaluated. Cells infected with a recombinant CTGV express-
ing the -galactosidase gene of E. coli were either left untreated
or were treated with 30 M BQR or 40 g/mL Ara-C. This drug is a
well-known inhibitor of DNA synthesis and, consequently, it does
not affect virus early gene expression, whereas late gene expres-
sion is shut off as a result of the inhibition of DNA replication [12].
Cells were collected at 6 h or 24 h post infection and the activ-
ity of -galactosidase was measured as described in Section 2.6.
As shown in Fig. 3c, BQR had minor effects on -galactosidase
activity at 6 h post infection, similar to the effect of Ara-C. On the
other hand, both drugs strongly inhibited -galactosidase activity
at 24 h post infection. These results conﬁrmed the Western blot
data shown in Fig. 3b, demonstrating that early gene expression
remained unaffected by BQR whereas post-replicative gene expres-
sion was severely inhibited in the presence of the drug. In addition,
because BQR acted similarly to Ara-C, this result also suggested that
virus DNA synthesis may  be the target of BQR.
To analyse this possibility further, BSC-40 cells were infected
with CTGV and were treated with 30 M BQR for 20 h, followed
by immunoﬂuorescence assay. Analysis of DAPI staining revealed
the presence of virosomes spread in the cytoplasm of untreated
infected cells, as would be expected for cells in late stage of the
cycle (Fig. 4, arrows). On the other hand, BQR treatment drasti-
cally reduced the formation of virosomes by 82.9%, and the few
that were observed were mostly in cells co-stained for virus late
proteins (Fig. 4, arrows). As a marker for virus late polypeptides,
the post-replicative envelope protein D8 as well as CTGV struc-
tural proteins (anti-VACV) were detected. Severe inhibition of D8
expression in the presence of BQR was observed in different ﬁelds
in distinct assays, similar to the results obtained for the detection
of CTGV structural proteins (Fig. 4). Cells positive for D8 and virus
structural proteins were occasionally visualised in the presence of
BQR, and cell counting revealed an 89.12% inhibition of positive
cells under this situation. These results conﬁrmed the data from
the Western blot and reporter gene analyses, revealing a strong
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Fig. 2. Effect of brequinar (BQR) on the replication of distinct orthopoxviruses and on Cantagalo virus (CTGV) infectivity. (a) Cells were infected (multiplicity of infection = 1)





















for  24 h. Virus yields were determined by plaque assay of the cell lysates. (b) Effect o
he  indicated concentrations of BQR for 1 h, followed by titration in BSC-40 cells. 
laque-forming units.
nhibition of post-replicative gene expression in the presence of
QR, and reinforced the suggestion that the drug probably targeted
irus DNA replication.
.2.2.  Virus DNA replication is inhibited by brequinar
Replication of virus DNA in the presence of BQR was eval-
ated next. Extracts of cells infected in the presence of 30 M
QR were collected at the indicated times of infection and were
ybridised to the 32P-HindIII D fragment of the VACV genome. As
hown in Fig. 5a, in untreated cells the accumulation of virus DNA
as initially detected at 6–8 h post infection and increased with
he progression of the cycle. On the other hand, when infection
ig. 3. Effect of brequinar (BQR) on Cantagalo virus (CTGV) replication during one-step 
TGV  [multiplicity of infection (MOI) = 1] and were treated with either 0.1% dimethyl sulp
ysates were prepared for determination of virus yield by plaque assay. Values represent 
rotein accumulation. Cells were infected and treated as described in (a), and at the indic
ntibodies against CTGV structural proteins or F11. -Tubulin was  also detected as a co
re  shown on the right. A representative experiment is shown. (c) Inhibition of late expre
MOI = 1) and were treated with either 0.1% DMSO (control), 30 M BQR or 40 g/mL cyto
or determination of -galactosidase activity as described in Section 2.6. Values represen on CTGV infectivity. Puriﬁed CTGV particles (4 × 106 PFU/mL) were incubated with
 represent the mean of at least two independent assays titered in duplicate. PFU,
proceeded in the presence of BQR, replication of virus genome was
severely repressed.
3.2.3.  Uridine counteracts the antiviral effect of brequinar
To  investigate whether viral DNA replication was  in effect the
primary target for BQR, infected cells were co-treated with 30 M
BQR and an excess of URD. The rationale of the assay was  to gener-
ate pyrimidines through the salvage pathway, thus bypassing the
effect of BQR on de novo biosynthesis. Addition of URD together
with BQR for 24 h completely restored normal levels of virus DNA
accumulation during infection (Fig. 5b). This was accompanied by
the recovery of virus late gene expression measured by the detec-
replicative cycles. (a) Time-course analysis of virus yield. Cells were infected with
hoxide (DMSO) (control) or 30 M BQR. At the indicated hours post infection, cell
the mean of two independent assays titered in duplicate. (b) Effect of BQR on virus
ated hours post infection cell lysates were prepared for Western blot analysis using
ntrol for protein loading. M,  mock-infected cells. Molecular weight markers (kDa)
ssion of -galactosidase by BQR. Cells were infected with recombinant CTGV-Gal
sine arabinoside (ARA-C). At 6 h and 24 h post infection, cell lysates were prepared
t the mean of at least two  independent assays. PFU, plaque-forming units.
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Fig. 4. Detection of virus DNA and late proteins by immunoﬂuorescence assay. Cells were infected with Cantagalo virus (CTGV) (multiplicity of infection = 1) and were
incubated with 0.1% dimethyl sulphoxide (DMSO) (control) or 30 M brequinar (BQR). At 20 h post infection, cells were ﬁxed, permeabilised and stained with antibodies
against virus late protein D8 or CTGV structural proteins. Cell nuclei and viral DNA were stained with 4′-6-diamidino-2-phenylindole (DAPI). Mock, mock-infected cells.
Arrows point to virosomes in the cell cytoplasm. Representative images are shown. Scale bars, 20 m.
Fig. 5. Effect of brequinar (BQR) on virus DNA accumulation and rescue of virus replication by uridine (URD). (a) Cells were infected with Cantagalo virus (CTGV) (multiplicity
of  infection = 1) and were treated with either 0.1% dimethyl sulphoxide (DMSO) (control) or 30 M BQR. At the indicated hours post infection, cell lysates were prepared for
slot-blot  assay. Viral DNA was detected by using the 32P-HindIII D fragment of the vaccinia virus (VACV) genome as probe. (b–d) URD restores normal levels of viral DNA
replication, late protein accumulation and virus progeny production. Experiments were performed as described in (a), except that URD, at the indicated concentrations, was
added  to the cells together with 30 M BQR or separately. At 24 h post infection, cell lysates were collected for (b) detection of viral DNA by slot-blot assay, (c) Western blot
analysis of CTGV structural proteins and -tubulin (protein loading control) and (d) determination of virus yield by plaque assay. In (c), the molecular weight markers (kDa)
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ion of CTGV structural proteins by Western blot (Fig. 5c). Most
mportantly, URD rescued normal production of CTGV infectious
articles during infection in the presence of BQR (Fig. 5d). Taken
ogether, these data demonstrated that the stage of virus DNA repli-
ation was the main target of the antiviral effect of BQR during CTGV
nfection.
. Discussion
CTGV is an emerging pathogen that causes a pustulovesicular
isease in dairy cows and dairy workers in Brazil [1]. Actions to
estrain the spread of the disease have been scarce, and numer-
us outbreaks have been reported in different states over the
ast decade [2–4]. No speciﬁc antiviral therapy is commercially
vailable, encouraging the search for natural and synthetic drugs
ffective against CTGV replication in vitro [7–9]. Here we demon-
trate that BQR severely inhibited CTGV production when added
uring infection, but no direct effect on the infectivity of the virus
articles was observed. A similar inhibitory effect of virus yield was
etected when other strains of VACV and CPXV were investigated.
A  detailed analysis of the CTGV replicative cycle revealed that
irus early gene expression was not inhibited in the presence of
QR, as shown by the accumulation of the early protein F11 to
ontrol levels. In addition, the expression of -galactosidase under
ontrol of a viral early/late promoter was not affected at early
imes. On the other hand, BQR clearly silenced virus late gene
xpression as demonstrated by Western blot assays, immunoﬂu-
rescence assays and the inhibition of -galactosidase activity at
4 h post infection. Further analysis revealed that a blockage in
irus DNA synthesis accounted for the ablation of post-replicative
ene expression. This conclusion was supported by the complete
escue of CTGV DNA synthesis and subsequent restoration of late
rotein accumulation and virus yield when URD was added to
nfected cells together with BQR. These data suggest that BQR tar-
eted CTGV DNA synthesis by inhibiting the de novo pathway,
eading to depletion of the intracellular pyrimidine pool. Therefore,
hese data are in agreement with previous work showing that BQR
nhibits the activity of cellular DHODH, a rate-limiting enzyme in
he de novo synthesis of pyrimidines [16]. A similar mechanism of
ction was recently reported for the antiviral effect of BQR against
he replication of dengue virus [19]. Based on the EC50 values, CTGV
ppears to be nearly 4.5 times more sensitive to the effect of BQR
han dengue virus. However, it is worth noting that the experiments
ere performed using different cell lines and distinct methods to
valuate virus production. Other inhibitors of de novo pyrimidine
iosynthesis have also been shown to be potent antiviral drugs
gainst RNA and DNA viruses in vitro [20–26].
However, in vivo studies have not been successful in demon-
trating the antiviral efﬁcacy of drugs involved in the inhibition
f de novo biosynthesis. Attempts to address the antiviral activity
f inhibitors of orotidylate decarboxylase against distinct viruses,
ncluding vaccinia virus inoculated intranasally in hamsters, have
ailed to show signiﬁcant reductions in virus load [26]. Simi-
arly, recent efﬁcacy studies using novel DHODH inhibitors against
engue virus and respiratory syncytial virus (RSV) in different ani-
al  models were not able to show reductions in virus yield [20,25].
he authors have raised the possibility that the high bioavailability
f extracellular pyrimidines for cell uptake would restore normal
ates of virus replication, therefore annulling the antiviral effect of
he drugs in vivo. For RSV infection, it was reported that increased
oses of the inhibitors were cytotoxic, and their immunosuppres-
ive activity did not favour the host to mount an immune response
25]. The authors suggested that the cellular de novo pathway may
ot be the target of choice for antiviral drugs. Nevertheless, Dunn
t al. [24] have recently demonstrated the in vivo efﬁcacy of anotherl of Antimicrobial Agents 38 (2011) 435– 441
DHODH  inhibitor, leﬂunomide, which reduced RSV load in rat lungs
by 3 log. However, the mechanism by which this drug restrained
RSV replication in vivo is still unknown and did not appear to result
from its ability to block the de novo biosynthesis of pyrimidines,
although this pathway seemed to be the target of leﬂunomide in
in vitro infections [24].
Several  immunosuppressants have been proven effective
against distinct VACV strains in cell culture, but they have not
been tested in animal models, thus no data are currently avail-
able to discuss their antiviral efﬁcacy in vivo [7,10–12,18,27].
Their immunosuppressive features would probably be an impor-
tant negative aspect in animal models but, on the other hand, these
compounds have proven to be excellent tools to study the involve-
ment of cellular pathways in the virus replicative cycle in vitro.
CsA, for example, had its antiviral activity against VACV correlated
with its ability to bind to and suppress the prolyl-peptidyl iso-
merase activity of cellular cyclophilin A [11,12]. This protein was
later reported to be recruited to virosomes during VACV infection
and be encapsidated into the core of mature virions [18].
Therefore, immunosuppressive drugs with antiviral activity
may turn out to be an interesting source for lead structures for
developing novel compounds with varied activities. Perhaps this
may  not apply to BQR because its immunosuppressive action
appears to be exerted through the same pathway by which its
antiviral activity is accomplished. However, it is worth noting that
CTGV infection in animals and humans produces a self-limited
disease that generates localised pustular lesions on the skin, and
topical antiviral therapy may  be indicated without the need for
systemic administration of the drug. In these cases, the putative
cytotoxic activity of the drug may  not compromise the antivi-
ral therapy. For instance, the off-label use of topical triﬂuridine
has been reported as the best option for treating VACV-associated
keratitis resultant from autoinoculation following exposure to
smallpox vaccine [28,29]. Similarly, topical cidofovir has been more
effective than parenteral cidofovir in treating progressive vaccinia
lesions on the skin of immunocompromised mice [30]. This is par-
ticularly important in view of the poor oral bioavailability and
limited intravenous use of cidofovir owing to nephrotoxicity [6].
Therefore, the current data on the antiviral effect of BQR against
CTGV replication are highly promising and it may be considered
for future assays as a topical antiviral therapy.
Acknowledgments
The authors thank DuPont Merck Pharmaceutical Company
(Wilmington, DE) for providing brequinar, and Ademilson Bizerra
(in memoriam) for technical assistance.
Funding: This work was  supported by grants from CNPq
(Conselho Nacional de Desenvolvimento Cientíﬁco e Tecnológico,
Brazil), FAPERJ (Fundac¸ ão Carlos Chagas Filho de Amparo à Pesquisa
do Estado do Rio de Janeiro, Brazil) and IFS (International Founda-
tion for Science, Sweden). LCS was the recipient of a fellowship
from Programa Institucional de Bolsas de Iniciac¸ ão Cientíﬁca
(PIBIC)/CNPq and currently receives a fellowship from CAPES.
Competing  interests: None declared.
Ethical approval: Not required.
References
[1] Damaso CR, Esposito JJ, Condit RC, Moussatche N. An emergent poxvirus from
humans  and cattle in Rio de Janeiro State: Cantagalo virus may derive from
Brazilian  smallpox vaccine. Virology 2000;277:439–49.[2]  Medaglia ML,  Pessoa LC, Sales ER, Freitas TR, Damaso CR. Spread of Cantagalo
virus  to northern Brazil. Emerg Infect Dis 2009;15:1142–3.
[3] Damaso CR, Reis SA, Jesus DM,  Lima PS, Moussatche N. A PCR-based assay for
detection  of emerging vaccinia-like viruses isolated in Brazil. Diagn Microbiol





















[L.C. Schnellrath, C.R. Damaso / International J
[4]  Quixabeira-Santos JC, Medaglia ML,  Pescador CA, Damaso CR. Animal move-
ment  and establishment of vaccinia virus Cantagalo strain in Amazon biome,
Brazil.  Emerg Infect Dis 2011;17:726–9.
[5] Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, editor.
Fields  virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
p.  2905–46.
[6]  Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses
in  animal models. Antivir Chem Chemother 2008;19:115–24.
[7] Reis SA, Moussatche N, Damaso CR. FK506, a secondary metabolite produced by
Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection
in  cell culture. J Appl Microbiol 2006;100:1373–80.
[8] Jordao AK, Afonso PP, Ferreira VF, de Souza MC,  Almeida MC,  Beltrame CO,
et  al. Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus
replication  in cell culture. Eur J Med  Chem 2009;44:3777–83.
[9]  Jesus DM, Moussatche N, Damaso CR. In vitro activity of cidofovir against the
emerging  Cantagalo virus and the smallpox vaccine strain IOC. Int J Antimicrob
Agents  2009;33:75–9.
10] Damaso CR, Oliveira MF,  Massarani SM,  Moussatche N. Azathioprine inhibits
vaccinia  virus replication in both BSC-40 and RAG cell lines acting on different
stages  of virus cycle. Virology 2002;300:79–91.
11] Damaso CR, Moussatche N. Inhibition of vaccinia virus replication by
cyclosporin  A analogues correlates with their afﬁnity for cellular cyclophilins.
J  Gen Virol 1998;79:339–46.
12] Damaso CR, Keller SJ. Cyclosporin A inhibits vaccinia virus replication in vitro.
Arch  Virol 1994;134:303–19.
13] Schuurman HJ, Tanner M,  Pally C, Jaffee BD. Brequinar and brequinar analogues
in  rat allo- and xenotransplantation. Transplant Proc 1998;30:2240–3.
14] Makowka L, Sher LS, Cramer DV. The development of brequinar as an immuno-
suppressive  drug for transplantation. Immunol Rev 1993;136:51–70.
15] Jaffee BD, Jones EA, Loveless SE, Chen SF. The unique immunosuppressive activ-
ity  of brequinar sodium. Transplant Proc 1993;25:19–22.
16] Chen SF, Perrella FW,  Behrens DL, Papp LM.  Inhibition of dihydroorotate dehy-
drogenase  activity by brequinar sodium. Cancer Res 1992;52:3521–7.
17] Xu X, Williams JW,  Shen J, Gong H, Yin DP, Blinder L, et al. In vitro and in vivo
mechanisms  of action of the antiproliferative and immunosuppressive agent,
brequinar  sodium. J Immunol 1998;160:846–53.
18]  Castro AP, Carvalho TM,  Moussatche N, Damaso CR. Redistribution of
cyclophilin  A to viral factories during vaccinia virus infection and its incor-
poration  into mature particles. J Virol 2003;77:9052–68.
[l of Antimicrobial Agents 38 (2011) 435– 441 441
19] Qing M,  Zou G, Wang QY, Xu HY, Dong H, Yuan Z, et al. Characterization
of dengue virus resistance to brequinar in cell culture. Antimicrob Agents
Chemother  2010;54:3686–95.
20] Wang QY, Bushell S, Qing M,  Xu HY, Bonavia A, Nunes S, et al. Inhibition
of  dengue virus through suppression of host pyrimidine biosynthesis. J Virol
2011;85:6548–56.
21]  Waldman WJ,  Knight DA, Blinder L, Shen J, Lurain NS, Miller DM,  et al. Inhibition
of  cytomegalovirus in vitro and in vivo by the experimental immunosuppres-
sive  agent leﬂunomide. Intervirology 1999;42:412–8.
22] Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW,  Chong AS,
Waldman  WJ.  Inhibition of herpes simplex virus type 1 by the exper-
imental  immunosuppressive agent leﬂunomide. Transplantation 2001;71:
170–4.
23] Evers  DL, Wang X, Huong SM, Andreoni KA, Huang ES. Inhibition of human
cytomegalovirus signaling and replication by the immunosuppressant FK778.
Antiviral  Res 2005;65:1–12.
24] Dunn MC,  Knight DA, Waldman WJ.  Inhibition of respiratory syncytial virus
in  vitro and in vivo by the immunosuppressive agent leﬂunomide. Antivir Ther
2011;16:309–17.
25] Bonavia  A, Franti M,  Pusateri Keaney E, Kuhen K, Seepersaud M,  Radetich B,
et  al. Identiﬁcation of broad-spectrum antiviral compounds and assessment of
the  druggability of their target for efﬁcacy against respiratory syncytial virus
(RSV).  Proc Natl Acad Sci U S A 2011;108:6739–44.
26]  Smee DF, McKernan PA, Nord LD, Willis RC, Petrie CR, Riley TM,  et al. Novel
pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral
activity.  Antimicrob Agents Chemother 1987;31:1535–41.
27]  Smee DF, Bray M, Huggins JW.  Antiviral activity and mode of action studies of
ribavirin  and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem
Chemother  2001;12:327–35.
28] Altmann S, Brandt CR, Murphy CJ, Patnaikuni R, Takla T, Toomey M,  et al.
Evaluation  of therapeutic interventions for vaccinia virus keratitis. J Infect Dis
2011;203:683–90.
29]  Fillmore GL, Ward TP, Bower KS, Dudenhoefer EJ, Grabenstein JD, Berry GK,
et  al. Ocular complications in the Department of Defense Smallpox Vaccination
Program.  Ophthalmology 2004;111:2086–93.
30] Smee DF, Bailey KW,  Wong MH,  Wandersee MK,  Sidwell RW.  Topical
cidofovir is more effective than is parenteral therapy for treatment of
progressive  vaccinia in immunocompromised mice. J Infect Dis 2004;190:
1132–9.
